Alvarez et al., 2009). In addition, species of Rhizomucor, Apophysomyces, Saksenaea, Cunninghamella, Cokeromyces, and Syncephalastrum have also been described as caustaive agents of mucormycosis, but less cases have been reported (Gomes et al., 2011). Five major forms of mucormycosis occur, including rhino-orbito-cerebral, pulmonary, disseminated, cutaneous, and gastrointestinal, while species of Entomophthoromycotina generally cause locally manifested-cutaneous and subcutaneousand slowly progressive infections (Prabhu and Patel, 2004; Pfaller and Diekema, 2005). An increase in the number of mucormycosis has been observed in the last few decades, mainly because of the modern surgical interventions, immunosuppressive therapies and irresponsible use of antimicrobial agents (Ribes et al., 2000; Chayakulkeeree, et al., 2006; Ibrahim et al., 2012). According to Centers for Disease Control and Prevention USA (CDC, 2015) the overall mortality rate of mucormycosis found to be 54%. It was 46% among people with sinus infections, 76% for pulmonary infections, and 96% for disseminated mucormycosis (CDC, 2015). The most vulnerable group of these infections are immunocompromised patients, the major risk factors include neutropenia, cancer, corticosteroid treatment, diabetes mellitus in ketoacidosis, deferoxamine treatment, organ transplantation, and burn injury (Sugar, 2000; Sugar and Liu, 2000; Prabhu and Patel, 2004; Ibrahim et al., 2008). Phagocytes-primarily macrophages and neutrophils-have the most important role in host immune defence against fungi causing mucormycosis, thus longer neutropenia is one of the major risk for developing infection (Ibrahim et al, 2012; Morace and Borghi, 2012). Pulmonary alveolar macrophages play important role in defence against these fungi, because inhalation of the sporangiospores is one of the most common way of infection (van de Veerdonk et al., 2010). 3.3. Antifungal agents applied in clinics to treat fungal infections Only few antimycotic drugs were reported which are able to kill the Mucoromycotina fungi, whereas others merely only inhibit the growth of pathogens. The proper antifungal therapy and selection of drug should be based on several criteria, such as immune capability of the host, site of infection, characteristics of the infection (the fungal species and its susceptibility to different antifungal drugs), and pharmacokinetic characteristics of the antifungal drug (e.g., absorption, elimination, and toxicity) (Lepak et al., 2015). Mucorales are mostly resistant against widely used antifungal drugs used in clinics (such as against different azoles and echinocandins), thus generally, antifungal therapy need to be combined with surgical debridement of the necrotic regions.